Study: Multicenter randomized phase III trial comparing first-line osimertinib plus carboplatin–pemetrexed followed by osimertinib–pemetrexed maintenance versus osimertinib alone in advanced NSCLC harboring both an EGFR-sensitizing mutation and a concurrent TP53 mutation.

Key data: N=294. Median PFS was 34.0 vs 15.6 months; HR 0.44, (95% CI, 0.32–0.60). Benefit was consistent across prespecified subgroups, including patients with baseline brain metastases and L858R. OS remained immature at 30.6% maturity, with a numerical trend favoring combination therapy. Grade ≥3 TRAEs occurred in 62.4% vs 14.9%.

Why it matters: Identifies a high-risk molecularly defined EGFR-mutated population in which first-line chemotherapy intensification produces a particularly large PFS benefit.

Clinical context & caveats: The trial included only TP53-mutated tumors, so it does not establish TP53 as a predictive biomarker relative to TP53-wildtype disease. The study was conducted exclusively in China, OS remains immature, and the PFS benefit comes with substantially greater hematologic toxicity and treatment burden.

Link

Study: Updated analysis of the randomized double-blind phase III AEGEAN trial comparing neoadjuvant durvalumab plus platinum-based chemotherapy followed by surgery and adjuvant durvalumab versus perioperative placebo plus chemotherapy in resectable stage II–IIIB (N2) NSCLC.

Key data: Modified ITT population N=740 after excluding documented EGFR/ALK alterations. At a median follow-up of 25.9 months, EFS continued to favor perioperative durvalumab; HR 0.69, (95% CI, 0.55–0.88). Median EFS was not reached vs 30.0 months. Interim DFS in the resected population favored durvalumab; HR 0.66 (95% CI, 0.47–0.92). OS remained immature. During adjuvant treatment, grade 3–4 AEs occurred in 15.4% vs 10.6%.

Why it matters: Confirms that the EFS benefit of perioperative durvalumab is durable and provides the first emerging DFS and OS context after completion of treatment.

Clinical context & caveats: OS benefit has not yet been demonstrated, and the trial cannot determine how much of the benefit derives from neoadjuvant versus adjuvant durvalumab. DFS remains an interim analysis.

Link

Study: Multicenter open-label single-arm phase IIb trial evaluating sutetinib in locally advanced or metastatic NSCLC harboring G719X, S768I, L861Q, or predefined compound EGFR mutations without prior EGFR-TKI exposure.

Key data: N=99; 96 efficacy-evaluable. IRC-confirmed ORR was 70.8%, DCR 90.6%, median DoR 12.0 months, and median PFS 13.7 months. Patients with compound mutations had ORR 84.4% versus 64.1% with solitary mutations and median PFS 13.8 vs 11.0 months. Grade ≥3 TRAEs occurred in 42.4%, most commonly diarrhea (28.3%) and hypokalemia (8.1%). Dose reduction was required in 34.3%.

Why it matters: Adds prospective evidence in uncommon EGFR-mutated NSCLC, where optimal TKI selection remains considerably less defined than for exon 19 deletion or L858R disease.

Clinical context & caveats: Single-arm study with predominantly Chinese enrollment. Cross-trial comparisons with afatinib, osimertinib, and other TKIs are unreliable, and diarrhea was clinically significant.

Link

Study: Randomized double-blind phase III trial comparing the second-generation EGFR-TKI mefatinib with gefitinib in untreated advanced nonsquamous NSCLC with EGFR exon 19 deletion or L858R.

Key data: N=336. Median IRC-assessed PFS was 13.7 vs 9.7 months; HR 0.68 (95% CI, 0.53–0.87). ORR was similar, 81.2% vs 77.9%. The benefit was most apparent in L858R disease, with median PFS 13.7 vs 8.3 months; HR 0.55. Median OS was 35.4 vs 33.3 months; HR 0.90, p=0.577. Grade ≥3 TRAEs occurred in 45.7% vs 24.8%, including grade ≥3 diarrhea in 20.2% vs 0.9%.

Why it matters: Shows activity of another second-generation EGFR inhibitor and suggests potentially greater relative benefit in L858R disease.

Clinical context & caveats: Gefitinib is no longer the most relevant first-line comparator in many settings, where osimertinib and combination strategies are established. Patients with brain metastases were excluded, and no significant OS improvement was demonstrated.

Link

Study: Randomized phase III ALCHEMIST-ALK trial comparing up to 2 years of adjuvant crizotinib with placebo or observation after complete resection of ALK-positive NSCLC.

Key data: N=166 enrolled; 153 had centrally confirmed ALK-positive disease. After median follow-up of 65.7 months, median DFS was 74.6 months with crizotinib versus 106.2 months with observation/placebo; HR 1.08 (95% CI, 0.61–1.90). Grade ≥3 AEs occurred in 58% receiving crizotinib and serious AEs in 27%. Fewer than half of patients completed the planned 2 years of therapy.

Why it matters: Demonstrates that efficacy of ALK inhibition in advanced disease cannot simply be extrapolated to the adjuvant setting and that the choice of ALK inhibitor matters.

Clinical context & caveats: The study was designed before modern ALK inhibitors and stopped accrual after adjuvant alectinib became available. Its relevance is therefore primarily practice-confirming: crizotinib should not be substituted for modern adjuvant ALK therapy.

Link

Study: Japanese randomized phase III noninferiority trial comparing daily low-dose carboplatin with weekly carboplatin plus nab-paclitaxel during thoracic radiotherapy in patients aged ≥75 years with unresectable locally advanced NSCLC. Consolidation durvalumab was recommended when feasible.

Key data: N=124. The trial was terminated early after the predictive probability of demonstrating noninferiority for the experimental regimen was only 8.0%. Median OS was not estimable with daily carboplatin versus 26.1 months with carboplatin/nab-paclitaxel; HR 1.56 (95% CI, 0.79–3.11). Durvalumab was subsequently initiated in 77% vs 70%. Two treatment-related deaths and seven additional non-cancer deaths occurred in the experimental arm, versus no treatment-related or non-cancer deaths with daily carboplatin.

Why it matters: Provides rare randomized evidence specifically for patients aged ≥75 years and argues against assuming that a more intensive platinum-doublet CRT regimen improves outcomes in this population.

Clinical context & caveats: Daily low-dose carboplatin with radiotherapy is a Japan-specific standard and is not routinely used internationally. The study stopped early and OS estimates remain immature.

Link

Study: Multicenter single-arm phase II trial of first-line platinum–etoposide plus durvalumab followed by durvalumab–olaparib maintenance, with integrated genomic, methylation, transcriptomic, and cytokine profiling.

Key data: N=60; 52 proceeded to durvalumab–olaparib maintenance. The 12-month alive and progression-free rate was 25.0%. ORR was 73.3%, median PFS from first-line treatment 6.8 months, and median OS 14.6 months. Median PFS from the start of maintenance was 3.9 months. Grade ≥3 TRAEs occurred in 36.7%. Multi-omics analysis identified a hypomethylation subgroup associated with superior survival and lower activity of selected DNA damage repair pathways.

Why it matters: The strongest signal may be biological rather than therapeutic: methylation patterns could eventually help identify an SCLC subgroup more sensitive to PARP-based maintenance strategies.

Clinical context & caveats: Single-arm phase II study with historical comparisons only. The efficacy of adding olaparib cannot be separated from standard chemo-immunotherapy without randomization, and the methylation signature is exploratory and requires independent prospective validation.

Link

TP53 may become relevant to treatment intensity in EGFR-mutated NSCLC. The magnitude of PFS benefit with osimertinib plus chemotherapy is striking, but a predictive TP53 interaction has not yet been proven.

Perioperative durvalumab continues to show durable EFS benefit, while the key remaining question is whether this translates into a clear OS advantage.

Not all targeted therapies within the same molecular class are interchangeable. Crizotinib failed in the adjuvant ALK setting, contrasting sharply with modern ALK inhibitors.

Uncommon EGFR mutations remain an active therapeutic niche. Sutetinib adds prospective activity data, but comparative trials are still needed to establish optimal sequencing.

Older patients deserve dedicated randomized evidence. JCOG1914 shows that greater chemotherapy intensity during CRT does not automatically translate into better outcomes and may worsen tolerability.

SCLC biomarker development is shifting beyond genomic mutations, with methylation and other epigenetic features emerging as possible tools for treatment selection.

The TP53-selected osimertinib study was conducted exclusively in China and did not include a TP53-wildtype comparator population; TP53 should therefore not yet be considered a validated predictive biomarker for chemotherapy benefit.

AEGEAN confirms EFS durability, but OS remains immature and the trial design cannot isolate the contribution of postoperative durvalumab.

Mefatinib was compared with gefitinib rather than a contemporary third-generation EGFR-TKI and excluded patients with brain metastases.

Sutetinib is supported by single-arm phase IIb data without an active comparator.

E4512 evaluated first-generation crizotinib and should not be generalized to newer ALK inhibitors.

JCOG1914 reflects Japanese treatment practice and enrolled only fit patients aged ≥75 years with ECOG 0–1.

The SCLC hypomethylation signature was generated from a small exploratory biomarker cohort and requires external validation.